Zacks.com Announces that Ian Wyatt Highlights the Following

Stocks: Intelligroup, j2 Global Communications, Bio-Imaging, 3Com, Colgate 
Palmolive, and Network Associates 
Business Editors
CHICAGO--(BUSINESS WIRE)--Nov. 17, 2003
Ian Wyatt can show you how to outsource your profit
potential with an IT services company on the rise, along with several
updates from his portfolio to help your returns grow strong. Read
about Intelligroup (NASDAQ:ITIG), j2 Global Communications
(NASDAQ:JCOM), Bio-Imaging (AMEX:BIT), 3Com (NASDAQ:COMS), Colgate
Palmolive (NYSE:CL), and Network Associates (NYSE:NET). Click here for
the full story exclusively on Zacks.com:
http://featuredexpert2bw.zacks.com/ 
Here are the highlights from the Featured Expert column: 
"Intelligroup - IT Outsourcing On The Cheap" from November 3, 2003 
Edison, New Jersey-based Intelligroup (NASDAQ:ITIG) is an
outsourced provider of IT services to companies world-wide. The
company services include software implementation, upgrades,
application development, and application management services.
Intelligroup is unique in that the company maintains a large number of
its developers in India where the cost of labor is low, while
maintaining headquarters in the United States and abroad to service
its growing base of worldwide clients. Current clients include 3Com
(NASDAQ:COMS), Colgate Palmolive (NYSE:CL), and Network Associates
(NYSE:NET). 
For the third quarter, Intelligroup reported revenues of $31
million, representing a 16% increase over the third quarter 2002, and
an 11% sequential increase over the previous quarter. Not including
special charges, Intelligroup reported an operating income of $975,000
and net earnings per share of five cents. It should be noted that
including these special charges, the company's net income was $214,000
and earnings per share were zero cents. During the conference call,
management provided financial guidance calling for 2003 revenues of
$116 - $118 million, which would provide for $39 - $41 million during
the fourth quarter, which would equate to sequential growth of 25 -
32%. Gross margins for the fourth quarter are expected to be 50%.
Meanwhile, full-year 2003 EPS are expected to be 14 - 16 cents. 
It is Ian Wyatt's belief that as this company becomes better known
to the investment community and if management is able to deliver on
the goals and projections communicated during the recent conference
call, there is an opportunity for significant upside in shares of
Intelligroup's stock. 
Portfolio Update from November 7, 2003 
Shares of j2 Global Communications (NASDAQ: JCOM) have fallen over
40% in the last month, even as the company provided stellar 2004
financial guidance. This provider of outsourced communications
services including the fast growing fax-to-e-mail service dubbed eFax
recently reaffirmed financial guidance for 2003 and announced that the
company expects to grow its revenues by 40% in 2004 while increasing
profit margins to a level that will result in EPS growth of 60%. Wyatt
and his team are increasing their rating on j2 and maintaining their
target price. With $44 million or $2 per share in cash on hand, Wyatt
and team believes j2 remains well positioned for continued high growth
in the next several years. 
Bio-Imaging (AMEX:BIT) recently reported financial results that
were in-line with Wyatt's, and apparently others since the stock
remained relatively steady in the $6 - $7 range. Revenues for the
quarter reached $6.3 million, a 16.5% increase over the same period in
2002. Net income for the quarter increased 28% to $527,000, or $0.05
cents per diluted share in the third quarter. Bio-Imaging CEO Mark
Weinstein wrote, "As we look to the remainder of 2003, we anticipate
our total revenues for 2003 to be in the range of $24 - $26 million
and diluted earnings per share to be in the range of $0.15 to $0.16
per share. As we previously indicated, for 2004, we expect total
revenue growth in excess of 20% and earnings per share growth in
excess of 30%." 
This guidance illustrates Wyatt's long-term position since he
initiated coverage of Bio-Imaging on July 23rd 2003. This company has
continued to perform within his estimates and he looks at 2004 with
expectations that the company can meet his 12 month price target 
Read a lot more information on Intelligroup and all of the
positions in Ian Wyatt's portfolio by clicking:
http://featuredexpert3bw.zacks.com/ 
About Zacks Featured Experts 
To be a successful investor you need professional advice. Experts
who know what they're talking about and can help you achieve your
financial goals in good markets...and especially in bad ones will help
you improve your portfolio. That is why Zacks Investment Research has
assembled the best investment experts in the business to offer their
powerful advisory newsletters to you on all the major investment
topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. 
Recommendations from Featured Experts Highlighted in FREE
Investment Newsletter 
The best way to tap into the powerful advice from these experts is
through our free weekly e-mail newsletter, "Profit from the Pros".
Each week we highlight several Featured Experts in this free e-mail
newsletter. Get your free subscription to "Profit from the Pros" at:
http://www.freeprofit1bw.zacks.com 
About Zacks 
Zacks.com is a property of Zacks Investment Research, Inc., which
was formed in 1978 to compile, analyze, and distribute investment
research to both institutional and individual investors. The guiding
principle behind our work is the belief that investment experts, such
as brokerage analysts and investment newsletter writers, have superior
knowledge about how to invest successfully. Our goal is to unlock
their profitable insights for our customers. And there is no better
way to enjoy this investment success, than with a FREE subscription to
"Profit from the Pros" weekly e-mail newsletter. For your free
newsletter, visit http://www.freeprofitbw.zacks.com 
Zacks Investment Research is under common control with affiliated
entities (including a broker-dealer and an investment adviser), which
may engage in transactions involving the foregoing securities for the
clients of such affiliates. 
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an offer
or solicitation to buy or sell any security. 
CONTACT:
Zacks.com
Terry Batey, 312-630-9880 x 307
myzacks@zacks.com
www.Zacks.com